PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
DERM vs. SGMO
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between DERM and SGMO is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

DERM vs. SGMO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Journey Medical Corporation (DERM) and Sangamo Therapeutics, Inc. (SGMO). The values are adjusted to include any dividend payments, if applicable.

0.00%100.00%200.00%300.00%400.00%500.00%600.00%AugustSeptemberOctoberNovemberDecember2025
-32.96%
174.68%
DERM
SGMO

Key characteristics

Sharpe Ratio

DERM:

-0.34

SGMO:

0.88

Sortino Ratio

DERM:

0.02

SGMO:

2.33

Omega Ratio

DERM:

1.00

SGMO:

1.31

Calmar Ratio

DERM:

-0.40

SGMO:

1.46

Martin Ratio

DERM:

-1.20

SGMO:

3.22

Ulcer Index

DERM:

23.65%

SGMO:

45.10%

Daily Std Dev

DERM:

84.18%

SGMO:

165.06%

Max Drawdown

DERM:

-89.55%

SGMO:

-99.40%

Current Drawdown

DERM:

-63.03%

SGMO:

-97.80%

Fundamentals

Market Cap

DERM:

$76.46M

SGMO:

$563.24M

EPS

DERM:

-$0.92

SGMO:

-$1.24

Total Revenue (TTM)

DERM:

$42.51M

SGMO:

$50.25M

Gross Profit (TTM)

DERM:

$23.87M

SGMO:

$45.15M

EBITDA (TTM)

DERM:

-$11.81M

SGMO:

-$67.72M

Returns By Period

In the year-to-date period, DERM achieves a -6.39% return, which is significantly lower than SGMO's 6.86% return.


DERM

YTD

-6.39%

1M

-22.29%

6M

-32.97%

1Y

-26.51%

5Y*

N/A

10Y*

N/A

SGMO

YTD

6.86%

1M

-53.62%

6M

174.49%

1Y

162.21%

5Y*

-33.55%

10Y*

-22.73%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

DERM vs. SGMO — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DERM
The Risk-Adjusted Performance Rank of DERM is 2727
Overall Rank
The Sharpe Ratio Rank of DERM is 2929
Sharpe Ratio Rank
The Sortino Ratio Rank of DERM is 3333
Sortino Ratio Rank
The Omega Ratio Rank of DERM is 3333
Omega Ratio Rank
The Calmar Ratio Rank of DERM is 2323
Calmar Ratio Rank
The Martin Ratio Rank of DERM is 1616
Martin Ratio Rank

SGMO
The Risk-Adjusted Performance Rank of SGMO is 8181
Overall Rank
The Sharpe Ratio Rank of SGMO is 7575
Sharpe Ratio Rank
The Sortino Ratio Rank of SGMO is 8585
Sortino Ratio Rank
The Omega Ratio Rank of SGMO is 8484
Omega Ratio Rank
The Calmar Ratio Rank of SGMO is 8585
Calmar Ratio Rank
The Martin Ratio Rank of SGMO is 7474
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

DERM vs. SGMO - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Journey Medical Corporation (DERM) and Sangamo Therapeutics, Inc. (SGMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for DERM, currently valued at -0.34, compared to the broader market-2.000.002.004.00-0.340.88
The chart of Sortino ratio for DERM, currently valued at 0.02, compared to the broader market-4.00-2.000.002.004.000.022.33
The chart of Omega ratio for DERM, currently valued at 1.00, compared to the broader market0.501.001.502.001.001.31
The chart of Calmar ratio for DERM, currently valued at -0.40, compared to the broader market0.002.004.006.00-0.401.50
The chart of Martin ratio for DERM, currently valued at -1.20, compared to the broader market-10.000.0010.0020.0030.00-1.203.22
DERM
SGMO

The current DERM Sharpe Ratio is -0.34, which is lower than the SGMO Sharpe Ratio of 0.88. The chart below compares the historical Sharpe Ratios of DERM and SGMO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00AugustSeptemberOctoberNovemberDecember2025
-0.34
0.88
DERM
SGMO

Dividends

DERM vs. SGMO - Dividend Comparison

Neither DERM nor SGMO has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

DERM vs. SGMO - Drawdown Comparison

The maximum DERM drawdown since its inception was -89.55%, smaller than the maximum SGMO drawdown of -99.40%. Use the drawdown chart below to compare losses from any high point for DERM and SGMO. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%AugustSeptemberOctoberNovemberDecember2025
-63.03%
-89.26%
DERM
SGMO

Volatility

DERM vs. SGMO - Volatility Comparison

The current volatility for Journey Medical Corporation (DERM) is 13.18%, while Sangamo Therapeutics, Inc. (SGMO) has a volatility of 89.93%. This indicates that DERM experiences smaller price fluctuations and is considered to be less risky than SGMO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


20.00%40.00%60.00%80.00%100.00%AugustSeptemberOctoberNovemberDecember2025
13.18%
89.93%
DERM
SGMO

Financials

DERM vs. SGMO - Financials Comparison

This section allows you to compare key financial metrics between Journey Medical Corporation and Sangamo Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab